Date: 2013-02-21
Type of information: Company acquisition
Acquired company: AROS Applied Biotechnology (Denmark)
Acquiring company: Eurofins Scientific (Luxembourg)
Amount:
Terms: Eurofins Scientific, a global leader in bio-analytical testing, and one of the global market leaders in genomic services, has acquiredAROS Applied Biotechnology A/S (AROS), aprovider of genomic solutions in Europe, serving the pharmaceutical industry, as well as academic and public research institutes.
Details: Founded in 2000 to provide GLP-approved genomic solutions to the pharmaceutical industry for the discovery and the development of new drugs, AROS generates revenues of about € 10 million. It has strong relationships with large pharmaceutical companies and research institutes, and over the last couple of years, has built a leading position in Next-Generation Sequencing (NGS) for pharmaceutical research purposes, its main revenue growth engine. This competence is strategically aligned with Eurofins' strength as one of the largest commercial NGS providers in the world, through Eurofins MWG Operon. As one of the pioneering NGS providers, Eurofins MWG Operon is the preferred partner of many public and private research laboratories and institutions. The addition of AROS into its genomic services network reinforces Eurofins' position as a leading testing provider to the pharmaceutical industry, and expands its genomic services footprint into the Nordic region, in addition to its laboratories in Europe, US, India, and Japan. It also complements Eurofins' technological platform with additional state-of-the-art capabilities in genotyping and expression profiling.
Related: Genomic services
